Evusheld is a medication used to prevent infection from COVID-19 before exposure to the virus, but it's not a vaccine. Evusheld is made up of two monoclonal antibodies (tixagevimab and cilgavimab) that are given as separate injections into the muscles, one right after the other. Evusheld originally received an emergency use authorization (EUA) from the FDA for certain people ages 12 years and older. But the FDA removed the EUA in 2023 because more recent findings show Evusheld has limited protection against the newer COVID-19 variants that make up a majority of COVID-19 infections in the United States.
Prevention of COVID-19 infections in certain people who aren't infected with COVID-19 and who haven't been exposed to anyone with COVID-19 (pre-exposure prevention, or PrEP)
Evusheld is made up of two separate monoclonal antibodies, tixagevimab and cilgavimab. They find and attach to different parts of the spike protein of the COVID-19 virus. The virus uses its spike protein to enter and infect your cells. When tixagevimab and cilgavimab bind to the spike protein, it blocks the COVID-19 virus from getting into your cells and causing further infection.
Source:Â DailyMed
Provides protection from the COVID-19 virus for at least 6 months
Can be used in children as young as 12 years old
Few side effects
Need to get 2 injections, one right after the other
Might need a repeat dose after 6 months
Not much research in pregnancy, breastfeeding, people with liver problems, and children under 12 years old weighing less than 88 lbs
Evusheld is no longer available or authorized in the United States. If you're concerned about COVID-19 and curious about your options for vaccines, prevention, or treatment, talk with your provider.
Some people have developed rare, but serious allergic reactions after receiving Evusheld. Because of this, your provider will ask you to stay at the clinic for at least 1 hour after your injections to monitor you for any serious allergic reactions. Symptoms can include wheezing, fast breathing, swelling under the skin, rash, hives, tightening of your throat, lightheadedness, and fainting. Please plan for this time when you go to your appointment.
This medication might put you at higher risk for serious heart problems, such as heart attacks and heart failure. Get medical attention right away if you experience chest pain or discomfort, difficulty breathing, swelling in your hands or feet, dizziness, or tiredness.
Evusheld can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Past allergic reaction to COVID-19 vaccines | Allergy to polysorbate 80 or polyethylene glycol (PEG)
Some people have experienced very serious allergic reactions after receiving Evusheld. To be safe, your provider will ask you to stay at the clinic for at least an hour after your injections. They'll monitor you for possible allergic reactions like trouble breathing, fast heart beat, dizziness, and fainting. If needed, they'll provide prompt medical treatment.
In addition, Evusheld contains an inactive ingredient called polysorbate 80, which is also found in some COVID-19 vaccines. If you've had a reaction to a COVID-19 vaccine in the past or if you have a known allergy to polysorbate 80 or polyethylene glycol (PEG), let your provider know before you receive this medication.
Evusheld isn't able to provide protection against all COVID-19 variants. You might get sick from COVID even after receiving this medication. Get medical help right away if you think you might have COVID or if you experience COVID symptoms like fever, chills, body aches, or lost of taste or smell.
Risk factors: Low platelets | History of bleeding problems
As with any injections that are given into the muscles, Evusheld can cause bleeding problems. Let your provider know if you have low platelets or a history of bleeding problems, they'll monitor you for serious bleeds after your injection.
Risk factors: History of heart problems, such as heart attack or stroke | High blood pressure | High cholesterol | High blood sugar (diabetes) | Obesity
Though rare, more people who received Evusheld reported serious heart problems, such as heart attack and heart failure, compared to people who didn't receive treatment in early studies. The link between serious heart problems and Evusheld use is still unclear. But the people who developed these problems after receiving the medication already had a history of or had risk factors for heart problems. Make sure your provider knows your full medical history before starting Evusheld. Get medical help right away if you experience symptoms of heart problems, such as chest pain or discomfort, difficulty breathing, swelling in your hands or feet, dizziness, or tiredness.
People ages 12 years and older (at least 88 lbs): The full dose of Evusheld is made up of one injection (300 mg) of tixagevimab and one injection (300 mg) of cilgavimab. They're injected into the muscles one right after the other (preferably one in each buttock), by a healthcare provider. The dose is repeated every 6 months.
Prevention of COVID-19 infections in certain people who aren't infected with COVID-19 and who haven't been exposed to anyone with COVID-19 (pre-exposure prevention, or PrEP)
Prevention of COVID-19 infections in people ages 12 and older
Prevention of COVID-19 infections in children ages 6 months to 11 years - EUA only
Prevention of COVID-19 infections in people 12 years and older
Prevention of COVID-19 infections in children 6 months to 11 years - EUA only
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
AstraZeneca Pharmaceuticals LP. (2023). Evusheld- azd7442 [package insert]. DailyMed.
U.S. Food and Drug Administration. (2021). Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals.
U.S. Food and Drug Administration. (2023). FDA announces Evusheld is not currently authorized for emergency use in the U.S.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.